Duavee & Breast Cancer: Promising New Study Results
- A medication already approved by the FDA to alleviate hot flashes and other menopausal symptoms may also offer a protective effect against invasive breast cancer,according to new,preliminary research.
- The study suggests that women at an elevated risk for breast cancer,particularly those with a history of "high-risk lesions" and who are experiencing menopausal symptoms,could benefit most from...
- Ductal carcinoma in situ (DCIS), or stage 0 breast cancer, affects over 60,000 women in the U.S.
A groundbreaking study reveals a potential link between a medication for menopausal symptoms and a reduced risk of invasive breast cancer—the primary_keyword—offering a promising new avenue for women at high risk. preliminary research suggests this drug may offer protective effects, particularly for women experiencing menopausal symptoms and with a history of high-risk lesions; the secondary_keyword considered. While the results are preliminary, the findings presented at the American Society of clinical Oncology (ASCO) Annual Meeting are intriguing, sparking hope for new preventative options. News Directory 3 brings you the latest updates from the study, emphasizing the need for further inquiry before concrete preventative measures can be confirmed.Discover what’s next as researchers plan larger, long-term studies to explore the medication’s potential in breast cancer prevention.
Menopause Drug May Reduce Breast Cancer Risk,Study Shows
Updated June 6,2025
A medication already approved by the FDA to alleviate hot flashes and other menopausal symptoms may also offer a protective effect against invasive breast cancer,according to new,preliminary research. The findings were presented by Dr. Kulkarni, a breast surgeon at Northwestern Medicine, at the American Society of clinical Oncology (ASCO) Annual Meeting in Chicago.
The study suggests that women at an elevated risk for breast cancer,particularly those with a history of “high-risk lesions” and who are experiencing menopausal symptoms,could benefit most from the drug. for these women,standard hormone therapies are frequently enough not recommended,leaving them with limited options for managing menopause,according to a news release.
Ductal carcinoma in situ (DCIS), or stage 0 breast cancer, affects over 60,000 women in the U.S. annually. (Istock)
Kulkarni cautioned that the results are preliminary and have not yet been published in a medical journal. Additional research is necessary before the medication can be considered for breast cancer prevention.
Kulkarni told Fox News Digital, “Our findings suggest that CE/BZA may prevent breast cancer, but larger studies with several years of follow-up are needed before we would know this for sure.”
Post-menopausal patients reported fewer hot flashes while taking CE/BZA during the study. (Istock)
Dr. Sheheryar Kabraji, chief of breast medicine at Roswell Park Thorough Cancer Center, who was not involved in the study, called the findings “intriguing” but emphasized the need for further investigation. She noted that the study focused on one specific protein and did not directly demonstrate a reduction in DCIS recurrence or invasive cancer advancement.
kabraji added, “While intriguing, this study is highly preliminary.”
Kabraji also noted that patients on the therapy experienced improved vasomotor symptoms, such as fewer hot flashes, and no decline in quality of life. If proven effective in preventing breast cancer, CE/BZA could have fewer side effects than current preventative medications.
Kulkarni stressed that the medication is not a treatment for invasive breast cancer or DCIS. “right now, we can say that women who are concerned about their risk of developing breast cancer can consider this medication to treat their menopausal symptoms,” she said.
What’s next
Larger, long-term studies are planned to confirm whether the drug can be approved as a breast cancer prevention mechanism.